FASN inhibition as a potential treatment for endocrine-resistant breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FASN inhibition as a potential treatment for endocrine-resistant breast cancer
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-25
DOI
10.1007/s10549-021-06231-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer
- (2020) Chun Gong et al. ONCOGENE
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
- (2018) Giorgia Zadra et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming
- (2017) Phillip A. Geter et al. GENES & DEVELOPMENT
- Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation
- (2017) Dedra H. Fagan et al. Hormones & Cancer
- Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells
- (2017) J A Menendez et al. Oncogenesis
- FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression
- (2017) Timothy S. Heuer et al. EBioMedicine
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Pathways: Fatty Acid Synthase
- (2015) S. F. Jones et al. CLINICAL CANCER RESEARCH
- Abstract A54: First-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 as monotherapy or in combination - final results of dose escalation
- (2015) Andrew Brenner et al. MOLECULAR CANCER THERAPEUTICS
- Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation
- (2015) Lakshmi Reddy Bollu et al. Oncotarget
- Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression
- (2015) Richard Ventura et al. EBioMedicine
- Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas
- (2013) Lili Li et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer
- (2013) Chun-Liang Chen et al. PROSTATE
- Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity
- (2011) Suneng Fu et al. NATURE
- Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma
- (2008) Yu-Hong Li et al. Journal of Translational Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started